Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun 16;13(12):3015.
doi: 10.3390/cancers13123015.

Systematic Review on the Association of Radiomics with Tumor Biological Endpoints

Agustina La Greca Saint-Esteven  1 , Diem Vuong  1 , Fabienne Tschanz  2 , Janita E van Timmeren  1 , Riccardo Dal Bello  1 , Verena Waller  2 , Martin Pruschy  2 , Matthias Guckenberger  1 , Stephanie Tanadini-Lang  1
Affiliations
Review

Systematic Review on the Association of Radiomics with Tumor Biological Endpoints

Agustina La Greca Saint-Esteven et al. Cancers (Basel). .

Abstract

Radiomics supposes an alternative non-invasive tumor characterization tool, which has experienced increased interest with the advent of more powerful computers and more sophisticated machine learning algorithms. Nonetheless, the incorporation of radiomics in cancer clinical-decision support systems still necessitates a thorough analysis of its relationship with tumor biology. Herein, we present a systematic review focusing on the clinical evidence of radiomics as a surrogate method for tumor molecular profile characterization. An extensive literature review was conducted in PubMed, including papers on radiomics and a selected set of clinically relevant and commonly used tumor molecular markers. We summarized our findings based on different cancer entities, additionally evaluating the effect of different modalities for the prediction of biomarkers at each tumor site. Results suggest the existence of an association between the studied biomarkers and radiomics from different modalities and different tumor sites, even though a larger number of multi-center studies are required to further validate the reported outcomes.

Keywords: cancer; imaging biomarker; radiomics; tumor biology; tumor molecular marker.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flow diagram of the study selection process according to PRISMA guidelines [15].
Figure 2
Figure 2
Distribution of the number of patients in the studies included in the analysis.
See this image and copyright information in PMC

References

    1. Goossens N., Nakagawa S., Sun X., Hoshida Y. Cancer biomarker discovery and validation. Transl. Cancer Res. 2015;4:256–269. - PMC - PubMed
    1. Malone E.R., Oliva M., Sabatini P.J.B., Stockley T.L., Siu L.L. Molecular profiling for precision cancer therapies. Genome Med. 2020;12:8. doi: 10.1186/s13073-019-0703-1. - DOI - PMC - PubMed
    1. Song J., Yin Y., Wang H., Chang Z., Liu Z., Cui L. A review of original articles published in the emerging field of radiomics. Eur. J. Radiol. 2020;127:108991. doi: 10.1016/j.ejrad.2020.108991. - DOI - PubMed
    1. Lambin P., Leijenaar R.T.H., Deist T.M., Peerlings J., de Jong E.E.C., van Timmeren J., Sanduleanu S., Larue R., Even A.J.G., Jochems A., et al. Radiomics: The bridge between medical imaging and personalized medicine. Nat. Rev. Clin. Oncol. 2017;14:749–762. doi: 10.1038/nrclinonc.2017.141. - DOI - PubMed
    1. Bublil E.M., Yarden Y. The EGF receptor family: Spearheading a merger of signaling and therapeutics. Curr. Opin. Cell Biol. 2007;19:124–134. doi: 10.1016/j.ceb.2007.02.008. - DOI - PubMed

LinkOut - more resources